Melinda Magyari, MD, PhD, The Danish Multiple Sclerosis Center, Rigshospitalet, København, Denmark, discusses a study comparing patients with multiple sclerosis (MS) starting a high-efficacy disease-modifying therapy as first-time treatment versus starting medium-efficacy disease-modifying therapies as the first treatment choice. Results suggest that for patients with MS, starting high-efficacy disease-modifying therapies lowers the risk of Expanded Disability Status Scale (EDSS) score worsening and relapses compared to starting medium-efficacy disease-modifying therapies. Lastly, Dr Magyari outlines the importance of personalized medicine in MS. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.